Cambryn Biologics is cited as a major player in the plasma therapy market.
SARASOTA — A new report on the large growth potential of the plasma therapy market cited Sarasota-based Cambryn Biologics as a global leader in the field.
The report, from British market research firm Report Buyer, says total value of the plasma therapy market is projected to more than double, from $135.6 million in 2016 to $297.6 million in 2021, according to a statement. That's a compound annual growth rate of 14% over the next five years. The growth, the report states, “is mainly attributed to the high success rate of pure platelet-rich plasma therapy, less recovery time and (an) increase in health care expenditure worldwide.”
The report cites 10 companies as “major players operating in the plasma therapy market,” including Cambryn Biologics, one of two U.S.-based firms on the list. Cambryn Biologics manufacturers and develops biologic products for the management and treatment of “clotting factor deficiencies,” according to its website. It specializes in the extraction and purification of human plasma proteins. Sarasota entrepreneur Mark Famiglio founded the company.
The top geographical market for plasma therapy, according to the report, is North America, followed by Europe and the Asia-Pacific region.